Therapy Areas: Cardiovascular
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3
17 July 2019 - - The US Food and Drug Administration has granted orphan drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia, US-based Arrowhead Pharmaceuticals I...
Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1
16 July 2019 - - The US Food and Drug Administration has granted a Breakthrough Therapy Designation to DCR-PHXC for the treatment of patients with primary hyperoxaluria type 1, US-based ribonucleic ac...
Bayer wins US FDA approval for Gadato to assess myocardial perfusion and late gadolinium enhancement in adult patients with CAD
16 July 2019 - Healthcare company Bayer reported on Monday the receipt of US Food and Drug Administration (FDA) approval for Gadavist (gadobutrol) injection for use in cardiac magnetic resonance (MR) ...
AstraZeneca provides update on decision by US FDA for Farxiga in type-1 diabetes
16 July 2019 - AstraZeneca Plc (LON:AZN), a global, science-led biopharmaceutical company, announced on Monday the issue by the US Food and Drug Administration (FDA) of a complete response letter rega...
AstraZeneca announces grant by US FDA of Orphan Drug Designation to Imfinzi
15 July 2019 - AstraZeneca Plc (LON:AZN), a global, science-led biopharmaceutical company, announced on Friday the grant by the US Food and Drug Administration (FDA) of Orphan Drug Designation (ODD) t...
Dr. Reddy's Launches Over-the-Counter Store Brand Equivalent of Mucinex D Extended Release Tablets in Two Strengths in the US Market
12 July 2019 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched an over-the-counter store-brand equivalent of Mucinex D Extended Release Tabl...